HOLX Stock Recent News
HOLX LATEST HEADLINES
Medical technology company Hologic reported a higher third-quarter profit on Monday, driven by strong demand for its diagnostics and breast health products, but forecast revenue for the current quarter that fell short of Wall Street estimates.
Hologic (HOLX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.93 per share a year ago.
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Hologic (HOLX) and SONOVA HOLDING (SONVY). But which of these two stocks offers value investors a better bang for their buck right now?
Hologic (HOLX) acquires Endomag for $310M, enhancing its breast cancer surgery portfolio with innovative technologies like Magseed and Magtrace, aiming to improve patient care and outcomes globally.
Evaluate the expected performance of Hologic (HOLX) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
In the latest trading session, Hologic (HOLX) closed at $78.38, marking a +0.35% move from the previous day.
Hologic (HOLX) is likely to have delivered impressive performances across the GYN Surgical and Breast Health businesses in the third quarter of fiscal 2024.
Hologic (HOLX) benefits from its unique set of businesses, each underpinned by its durable growth drivers. The impressive YTD price rally, earnings prowess and attractive valuation make the stock a top investment pick.
Hologic (HOLX) closed the most recent trading day at $78.46, moving +1.45% from the previous trading session.
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.